Cell-free kinase inhibition panel
Biochemical assay · Isolated CDK/cyclin complexes and GSK3β [1]
AT7519 inhibited multiple CDKs and GSK3β; potency varied by kinase and assay.
| Endpoint | Reported result | Reference |
|---|---|---|
| CDK1/cyclin B activity | IC50 210 nM | [1] |
| CDK2/cyclin A activity | IC50 47 nM | [1] |
| CDK3/cyclin E activity | IC50 360 nM | [1] |
| CDK4/cyclin D1 activity | IC50 100 nM | [1] |
| CDK5/p35 activity | IC50 13 nM | [1] |
| CDK6/cyclin D3 activity | IC50 170 nM | [1] |
| CDK7/cyclin H/MAT1 activity | IC50 2400 nM | [1] |
| CDK9/cyclin T activity | IC50 <10 nM | [1] |
| GSK3β activity | IC50 89 nM | [1] |
| Aurora A activity | IC50 >10000 nM | [1] |
Literature-Reported Treatment Conditions
- Exposure duration
- Assay-dependent: CDK1 2 h; CDK2 4 h; CDK4/5/6 30 min; GSK3β 3 h; Aurora A 30 min.
- Method
- Cell-free concentration-response kinase assays; IC50 fitted from replicate curves in GraphPad Prism.
- Vehicle
- 2.5% DMSO reported for CDK4/6 assays only.
- Reported limits
- Compound concentration series, exact replicate n and uncertainty not specified in SI; external CDK3/7/9 assay conditions and salt form not specified. No recommended working concentration inferred.
Methods and source locations
Compound reported in the paper: AT7519; Compound label in the paper: AT7519
Compound-level research findings; no claim of Adooq lot testing or salt/formulation equivalence.
Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
CDK1/cyclin B activity: Radiometric filter-binding assay; histone H1; 45 µM ATP; 2 h. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
CDK2/cyclin A activity: Radiometric filter-binding assay; histone H1; 45 µM ATP; 4 h. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
CDK3/cyclin E activity: External kinase assay; detailed conditions not provided in retrieved SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
CDK4/cyclin D1 activity: ELISA-format GST-pRb phosphorylation assay; 30 min; 2.5% DMSO; ATP concentration not stated in SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
CDK5/p35 activity: DELFIA phosphorylation assay; biotinylated histone H1 peptide; 15 µM ATP; 30 min. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
CDK6/cyclin D3 activity: ELISA-format GST-pRb phosphorylation assay; 30 min; 2.5% DMSO; ATP concentration not stated in SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
CDK7/cyclin H/MAT1 activity: External kinase assay; detailed conditions not provided in retrieved SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
CDK9/cyclin T activity: External kinase assay; detailed conditions not provided in retrieved SI. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
GSK3β activity: Radiometric assay; glycogen synthase peptide 2; 15 µM ATP; 3 h. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)
Aurora A activity: Radiometric assay; Kemptide; 15 µM ATP; 30 min. — Supplementary Table 1 (PDF p. 1); kinase assay descriptions (pp. 2–3)